Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 4 of Short Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 4

Description of the concentration

On 21 October 2024, the European Commission received the notification of a proposed transaction by way of purchase of shares, which concerns the acquisition of sole control within the meaning of Article (3)(1)(b) of the EU Merger Regulation by entities controlled by funds managed by The Carlyle Group Inc., (“Carlyle”), over Baxter International Inc.’s (“Baxter”) kidney care business division, Vantive (“Vantive”). The business activities of the undertakings concerned are:

• Carlyle: Headquartered in Washington DC (USA), Carlyle is a global alternative asset manager, which manages funds that invest globally across three investment disciplines: (i) Global Private Equity (including corporate private equity, real estate and natural resources funds); (ii) Global Credit (including liquid credit, illiquid credit and real assets credit); and (iii) Investment Solutions (private equity fund of funds program, which include primary fund, secondary and related co-investment activities).

• Baxter: Headquartered in Deerfield, Illinois (USA), Baxter is a healthcare company, which develops, manufactures and markets products used in the treatment of patients suffering from haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

• Vantive: is the kidney care business division of Baxter. Vantive is primarily active in the supply of renal replacement therapy (“RRT”) products. Vantive’s operations have two primary divisions; (i) Chronic Therapies, comprised of the Peritoneal Dialysis (“PD”) and Haemodialysis (“HD”) product portfolios, and (ii) Acute Therapies (“AT”) which is comprised of Continuous Renal Replacement Therapy (“CRRT”) and other organ support therapies used in ICU care.

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111